



Practical Guidance for the Community Oncologist Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Don't get left behind as antibody drug conjugate (ADC) technology continues to pave the way for targeted treatment approaches for patients with metastatic triple negative breast cancer (TNBC)

Topic Highlights

- ▶ TNBC treatment challenges
- ▶ ADC mechanistic rationale
- ▶ Role of TROP2 in TNBC
- ▶ Case-based application of current data and recommendations

Time:

Date:

Institution:

Contact:

Email:

Zoom link:

FEATURED FACULTY